Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Sanidad Militar
versión impresa ISSN 1887-8571
Resumen
APARICIO-HERNANDEZ, RM; SILVA-CUEVAS, MA; VILLABONA-RIVAS, I y YUSTE-GUTIERREZ, AM. Positive assessment of drugs: february, march and april 2023. Sanid. Mil. [online]. 2023, vol.79, n.2, pp.111-117. Epub 05-Feb-2024. ISSN 1887-8571. https://dx.doi.org/10.4321/s1887-85712023000200008.
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency issued in February, March and April 2023, and considered of interest to healthcare professionals, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.
Palabras clave : Espironolactona (Qaialdo®); Futibatinib (Lytgobi®); Glofitamab (Columvi®); Ivosidenib (Tibsovo/Tidhesco®); Mavacamten (Camzyos®); Mirikizumab (Omvoh®); Niraparib/abiraterona acetate (Akeegar®); Pegunigalsidasa alfa (Elfabrio®); Pirtobrutinib (Jaypirca®); Ruxolitinib (Opzelura®); Sirolimus (Hyftor®); Tiosulfato sódico (Pedmarqsi®); Ublituximab (Briumvi®); Vacuna Covid-19, Recombinant with adjuvant (Bimervax®); Respiratory virus vaccine sincitial, Recombinant, Adjuvant (Arexvy®); Vadadustat (Vafseo®)..